Gainers
- Revelation Biosciences, Inc. (NASDAQ:REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares jumped 44.7% to $3.9650 after the company announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).
- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) gained 35.5% to $4.31 after Kennedy Lewis Investment Management LLC announced an offer to acquire Rapid Micro Biosystems.
- Color Star Technology Co., Ltd. (NASDAQ:CSCW) rose 33.5% to $0.1753.
- Dermata Therapeutics, Inc. (NASDAQ:DRMA) gained 25% to $0.68.
- Ipsidy Inc. (NASDAQ:AUID) surged 24.7% to $1.87.
- 374Water, Inc. (NASDAQ:SCWO) rose 20.1% to $3.3877.
- Tuniu Corporation (NASDAQ:TOUR) jumped 20% to $0.9999.
- HeartCore Enterprises, Inc. (NASDAQ:HTCR) gained 20% to $2.6334.
- IperionX Limited (NASDAQ:IPX) surged 17.4% to $6.34.
- Revlon, Inc. (NYSE:REV) surged 16.6% to $5.34 on continued post-bankruptcy volatility. The stock has been mentioned on social media as a potential short squeeze candidate.
- Aspen Aerogels, Inc. (NYSE:ASPN) shares gained 16.6% to $9.83 after the company announced its decision not to proceed with concurrent public offerings of common stock and green convertible senior notes due 2027.
- Franklin Covey Co. (NYSE:FC) jumped 13.5% to $43.16 after reporting Q3 results.
- AEye, Inc. (NASDAQ:LIDR) gained 12.7% to $1.9850.
- Kewaunee Scientific Corporation (NASDAQ:KEQU) jumped 12.3% to $15.45.
- Remark Holdings, Inc. (NASDAQ:MARK) jumped 9.5% to $0.4340.
- Northern Lights Acquisition Corp. (NASDAQ:NLIT) gained 9.2% to $10.41.
- Applied Therapeutics, Inc. (NASDAQ:APLT) rose 7.8% to $0.9487. Applied Therapeutics recently announced a $30 million public offering of common stock and warrants.
- ThermoGenesis Holdings, Inc. (NASDAQ:THMO) rose 7.1% to $0.2998.
Losers
- Cryptyde Inc. (NASDAQ:TYDE) fell 64.4% to $2.24.
- Akerna Corp. (NASDAQ:KERN) fell 51.4% to $0.1429 after the company announced pricing of a $10 million public offering.
- Renalytix Plc (NASDAQ:RNLX) dipped 40.5% to $2.3550.
- Enjoy Technology, Inc. (NASDAQ:ENJY) dipped 38% to $0.1786.
- Angion Biomedica Corp. (NASDAQ:ANGN) fell 36.8% to $1.0801. Angion Biomedica discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
- COMSovereign Holding Corp. (NASDAQ:COMS) shares fell 33.8% to $0.1642 after jumping over 60% on Wednesday.
- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) fell 33.7% to $0.1689. Allena Pharmaceuticals shares jumped 114% on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
- Duck Creek Technologies, Inc. (NASDAQ:DCT) fell 26.5% to $13.53 after the company issued Q4 and FY22 sales guidance below estimates. The company also reported a year-over-year decrease in Q3 EPS results.
- Biophytis S.A. (NASDAQ:BPTS) fell 25% to $1.05.
- Kalera Public Limited Company (NASDAQ:KAL) dropped 24.9% to $6.50.
- Endo International plc (NASDAQ:ENDP) fell 24.4% to $0.3949.
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) dipped 23.7% to $1.13.
- Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) fell 22.9% to $4.20.
- SMART Global Holdings, Inc. (NASDAQ:SGH) shares dipped 22.3% to $15.75. SMART Global reported upbeat results for its third quarter, but issued weak forecast for the current quarter. The company also agreed to acquire Stratus Technologies for $225 million in cash at closing and an earn-out payment of up to $50 million.
- Brickell Biotech, Inc. (NASDAQ:BBI) fell 21.6% to $0.1349 after jumping around 48% on Wednesday.
- Aditxt, Inc. (NASDAQ:ADTX) dropped 21.5% to $0.1570.
- Grove Collaborative Holdings, Inc. (NYSE:GROV) fell 21.1% to $4.82.
- Advanced Human Imaging Limited (NASDAQ:AHI) fell 20.9% to $0.56.
- Aeterna Zentaris Inc. (NASDAQ:AEZS) fell 19.7% to $0.2074.
- Borr Drilling Limited (NYSE:BORR) dropped 19.1% to $4.39.
- Exicure, Inc. (NASDAQ:XCUR) fell 19% to $2.2450 following effect of 1:30 reverse stock split.
- 9 Meters Biopharma, Inc. (NASDAQ:NMTR) declined 19% to $0.2695. 9 Meters Biopharma disclosed preliminary results from Phase 2 study of vurolenatide in short bowel syndrome.
- Canopy Growth Corporation (NASDAQ:CGC) dropped 18.7% to $2.8450 after the company announced it entered into exchange agreements with holders of approximately $198 million of convertible notes. Also, Piper Sandler lowered its price target on the stock from $4 to $3.
- Agile Therapeutics, Inc. (NASDAQ:AGRX) fell 18.2% to $1.26 after the company filed for an offering of up to approximately 15.75 million shares
- Hyperfine, Inc. (NASDAQ:HYPR) shares fell 17.6% to $2.2250. Hyperfine appointed Scott Huennekens as Interim President & CEO.
- The9 Limited (NASDAQ:NCTY) fell 16.2% to $1.7861.
- Codiak BioSciences, Inc. (NASDAQ:CDAK) declined 16.1% to $3.0555. Codiak BioSciences announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.
- Aethlon Medical, Inc. (NASDAQ:AEMD) fell 15.4% to $1.1250.
- Culp, Inc. (NYSE:CULP) declined 15.3% to $4.26 following Q4 results.
- NextPlay Technologies, Inc. (NASDAQ:NXTP) dropped 14.7% to $0.3350. NextPlay's In-Game Advertising unit, Hotplay entered into memorandum of understanding with Triplecom Media PVT.
- Avenue Therapeutics, Inc. (NASDAQ:ATXI) declined 14.4% to $0.2770.
- Evofem Biosciences, Inc. (NASDAQ:EVFM) fell 14.3% to $0.8403. Evofem Biosciences recently announced an agreement with a pharmacy benefit manager.
- Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) dropped 14.1% to $1.8650 as the company reported pricing of public offering of common stock.
- Can-Fite BioPharma Ltd. (NYSE:CANF) fell 13.8% to $0.8795. Can-Fite BioPharma shares jumped over 15% on Wednesday after the company announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
- Studio City International Holdings Limited (NYSE:MSC) dropped 13.8% to $1.87.
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) declined 13% to $1.95. Lexicon Pharmaceuticals reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy.
- Cooper-Standard Holdings Inc. (NYSE:CPS) fell 12.8% to $4.72.
- Connect Biopharma Holdings Limited (NASDAQ:CNTB) shares fell 12.2% to $0.87 after gaining around 9% on Wednesday.
- Icosavax, Inc. (NASDAQ:ICVX) dropped 11.4% to $6.21. Icosavax recently announced interim results from its Phase 1/1b clinical trial of its IVX-121 RSV F antigen in young and older adults.
- Femasys Inc. (NASDAQ:FEMY) fell 11.2% to $2.45 after gaining around 7% on Wednesday.
- Journey Medical Corporation (NASDAQ:DERM) dropped 9.4% to $3.37.
- Adagene Inc. (NASDAQ:ADAG) fell 9.1% to $1.89 after the company reported authorization of $10 million buyback program.
- The Simply Good Foods Company (NASDAQ:SMPL) dropped 8.5% to $37.69 folloiwng Q3 results.
- First Wave BioPharma, Inc. (NASDAQ:FWBI) shares fell 7.6% to $0.2958.
- Q&K International Group Limited (NASDAQ:QK) dropped 7.2% to $1.67.
